Here are Thursday's biggest analyst calls: SpaceX, Apple, Marvell, CME, Palantir, Nike, Amazon, Micron & more

Wall Street calls were broadly bullish, with multiple upgrades and initiations on names including Apple, Nice, Albemarle, Salesforce, CME, UniQure, SpaceX and others. Several notes highlighted AI-related upside, pricing power, and improving fundamentals, while Micron’s price target was doubled to $1,200 and Marvell’s to $385. The main negative call was Intuit, which was downgraded to Hold on expected share erosion and lower growth targets.

Analysis

The common thread is that equity analysts are rewarding companies that either control a scarce bottleneck or can reprice into scarcity. That favors names with leverage to constrained inputs or regulated capacity: memory in semis, power for AI infrastructure, and differentiated clinical/regulatory paths in biotech. The second-order loser set is more interesting than the winners — software and consumer franchises with “value-based” pricing pressure may see multiple compression because the market is starting to treat pricing power as a finite resource, not a perpetual feature.

In tech, the market is implicitly splitting AI beneficiaries into infrastructure owners versus software wrappers. The infrastructure names with tangible assets and long-duration contracts should keep outperforming on the back of lower perceived terminal risk, while software platforms that depend on monetization promises may face tougher scrutiny if customers resist seat-based or usage-based expansion. That creates a useful pair: long the companies monetizing actual capacity, short the ones where the growth narrative is increasingly about defending share against customers rather than expanding economic value.

Healthcare is behaving like a catalyst market, not a fundamentals market. The binary re-ratings in CNS, gene therapy, and specialty pharma suggest investors are underpaying for regulatory de-risking, but also overpaying for any program without a near-term filing or commercial proof point. The best asymmetry is in names where one decision can re-rate the equity multiple in weeks, while the downside is mostly time decay rather than permanent impairment.

The contrarian angle is that the bullish call cluster may be too complacent on duration. If AI capex, memory pricing, or power scarcity normalize even modestly in the next 2-3 quarters, the market could quickly rotate from “scarcity premium” to “peak earnings” narratives. That argues for owning the highest-conviction, contract-backed winners, but financing them with shorts or hedges in names where the market is already extrapolating multi-year acceleration without enough evidence.

Key Decisions for Investors

• Long IREN vs short a basket of high-multiple AI software names for 3-6 months: own the asset-backed power/GPU scarcity story while fading valuation where monetization is still aspirational. Risk: if software turns into direct AI distribution winners, the short leg can squeeze.
• Add to AMZN on any post-headline consolidation over the next 1-2 weeks; the setup favors a 12-18 month re-rating as cloud growth becomes the cleaner AI cash-flow expression. Risk/reward improves if the market starts valuing infra optionality over near-term retail noise.
• Initiate a tactical long in MU ahead of earnings as a call-spread structure rather than outright stock: the setup benefits from continued memory tightness, but the main risk is a guide-up that is already heavily anticipated. Use upside participation with defined downside.
• Long TLN as a medium-term hold, but hedge with shorter-dated power-policy/event risk. The thesis works only if contracted cash flow remains insulated while the market continues to price data-center demand durability.
• Avoid or underweight INTU into the next earnings/analyst-day window; the risk is not just slower growth, but multiple compression if price optimization is interpreted as share defense. Best use is as a relative short versus CRM if you want software exposure without relying on legacy pricing power.